SE0102168D0 - New use and new compounds - Google Patents

New use and new compounds

Info

Publication number
SE0102168D0
SE0102168D0 SE0102168A SE0102168A SE0102168D0 SE 0102168 D0 SE0102168 D0 SE 0102168D0 SE 0102168 A SE0102168 A SE 0102168A SE 0102168 A SE0102168 A SE 0102168A SE 0102168 D0 SE0102168 D0 SE 0102168D0
Authority
SE
Sweden
Prior art keywords
new
compounds
picropodophyllin
artherosclerosis
acromegaly
Prior art date
Application number
SE0102168A
Other languages
English (en)
Inventor
Olle Larsson
Magnus Axelson
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE0102168A priority Critical patent/SE0102168D0/sv
Publication of SE0102168D0 publication Critical patent/SE0102168D0/sv
Priority to US10/480,800 priority patent/US20040167208A1/en
Priority to EP02739049A priority patent/EP1397368A1/en
Priority to JP2003506278A priority patent/JP2004534078A/ja
Priority to AU2002314671A priority patent/AU2002314671B2/en
Priority to EP08150436A priority patent/EP1938818A3/en
Priority to US10/481,441 priority patent/US7348358B2/en
Priority to PCT/SE2002/001223 priority patent/WO2002102805A1/en
Priority to NZ53017202A priority patent/NZ530172A/xx
Priority to EP08150437A priority patent/EP1938819A3/en
Priority to KR10-2003-7016623A priority patent/KR20040030686A/ko
Priority to CN028162404A priority patent/CN1659171A/zh
Priority to PT04024370T priority patent/PT1498121E/pt
Priority to CA2455328A priority patent/CA2455328C/en
Priority to CNB028161904A priority patent/CN100503611C/zh
Priority to AU2002311731A priority patent/AU2002311731B8/en
Priority to CNA2009101347598A priority patent/CN101606929A/zh
Priority to ES04024370T priority patent/ES2333014T3/es
Priority to EP02741588A priority patent/EP1397369A1/en
Priority to EP04024370A priority patent/EP1498121B1/en
Priority to DK04024370T priority patent/DK1498121T3/da
Priority to JP2003506277A priority patent/JP5071910B2/ja
Priority to EP10153209A priority patent/EP2186513A1/en
Priority to DE60233601T priority patent/DE60233601D1/de
Priority to NO20035648A priority patent/NO332642B1/no
Priority to PCT/SE2002/001202 priority patent/WO2002102804A1/en
Priority to NZ530290A priority patent/NZ530290A/en
Priority to CA2451047A priority patent/CA2451047C/en
Priority to KR1020037016630A priority patent/KR100940055B1/ko
Priority to AT04024370T priority patent/ATE441411T1/de
Priority to NO20035647A priority patent/NO20035647L/no
Priority to US11/346,294 priority patent/US7709526B2/en
Priority to US12/021,530 priority patent/US7629381B2/en
Priority to US12/021,578 priority patent/US7662851B2/en
Priority to AU2009201542A priority patent/AU2009201542B2/en
Priority to JP2009134006A priority patent/JP2009242406A/ja
Priority to US12/508,218 priority patent/US8389747B2/en
Priority to AU2010200488A priority patent/AU2010200488A1/en
Priority to US12/714,107 priority patent/US20100216728A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
SE0102168A 2001-06-19 2001-06-19 New use and new compounds SE0102168D0 (sv)

Priority Applications (39)

Application Number Priority Date Filing Date Title
SE0102168A SE0102168D0 (sv) 2001-06-19 2001-06-19 New use and new compounds
DK04024370T DK1498121T3 (da) 2001-06-19 2002-06-19 Hidtil ukendt anvendelse af specifikke cyclolignaner
EP02741588A EP1397369A1 (en) 2001-06-19 2002-06-19 New use or cyclolignans and new cyclolignans
AT04024370T ATE441411T1 (de) 2001-06-19 2002-06-19 Verwendung von bestimmten cyclolignanen
JP2003506278A JP2004534078A (ja) 2001-06-19 2002-06-19 シクロリグナン類の新規の使用および新規のシクロリグナン類
AU2002314671A AU2002314671B2 (en) 2001-06-19 2002-06-19 New use of cyclolignans and new cyclolignans
EP08150436A EP1938818A3 (en) 2001-06-19 2002-06-19 Use of specific cyclolignans
US10/481,441 US7348358B2 (en) 2001-06-19 2002-06-19 Use of cyclolignans
PCT/SE2002/001223 WO2002102805A1 (en) 2001-06-19 2002-06-19 NEW USE Of CYCLOLIGNANS AND NEW CYCLOLIGNANS
NZ53017202A NZ530172A (en) 2001-06-19 2002-06-19 New use of cyclolignans and new cyclolignans
EP04024370A EP1498121B1 (en) 2001-06-19 2002-06-19 Use of specific cyclolignans
KR10-2003-7016623A KR20040030686A (ko) 2001-06-19 2002-06-19 시클로리그난의 신규의 용도 및 신규의 시클로리그난
CN028162404A CN1659171A (zh) 2001-06-19 2002-06-19 新用途或环木脂体以及新环木脂体
PT04024370T PT1498121E (pt) 2001-06-19 2002-06-19 Utilização de ciclolenhanos específicos
CA2455328A CA2455328C (en) 2001-06-19 2002-06-19 New use of cyclolignans and new cyclolignans
CNB028161904A CN100503611C (zh) 2001-06-19 2002-06-19 特定环木脂体的新用途
AU2002311731A AU2002311731B8 (en) 2001-06-19 2002-06-19 New use of specific cyclolignans
EP02739049A EP1397368A1 (en) 2001-06-19 2002-06-19 New use of specific cyclolignans
ES04024370T ES2333014T3 (es) 2001-06-19 2002-06-19 Uso de ciclolignanos especificos.
US10/480,800 US20040167208A1 (en) 2001-06-19 2002-06-19 Use or cyclolignans and new cyclolignans
EP08150437A EP1938819A3 (en) 2001-06-19 2002-06-19 Use of specific cyclolignans
CNA2009101347598A CN101606929A (zh) 2001-06-19 2002-06-19 苦鬼臼脂素的用途
NZ530290A NZ530290A (en) 2001-06-19 2002-06-19 Specific cyclolignans for treating insulin-like growth factor-1 receptor dependent diseases
EP10153209A EP2186513A1 (en) 2001-06-19 2002-06-19 Use of specific cyclolignans
DE60233601T DE60233601D1 (de) 2001-06-19 2002-06-19 Verwendung von bestimmten Cyclolignanen
NO20035648A NO332642B1 (no) 2001-06-19 2002-06-19 Anvendelse av picropodophyllin for fremstilling av et medikament for profylakse eller behandling av Ewings sarkom, glioblastoma, prostatacarcinoma, brystcarcinoma, magekreft, pankreatisk carcinoma, ovariecancer og endometrisk carcinoma
PCT/SE2002/001202 WO2002102804A1 (en) 2001-06-19 2002-06-19 New use of specific cyclolignans
JP2003506277A JP5071910B2 (ja) 2001-06-19 2002-06-19 特定のシクロリグナン類の新しい使用
CA2451047A CA2451047C (en) 2001-06-19 2002-06-19 Use of picropodophyllin derivatives for treatment of igf-1r mediated disorders
KR1020037016630A KR100940055B1 (ko) 2001-06-19 2002-06-19 특이성 시클로리그난의 신규한 용도
NO20035647A NO20035647L (no) 2001-06-19 2003-12-17 Ny anvendelse av cyclolignaner og nye cycloliganer
US11/346,294 US7709526B2 (en) 2001-06-19 2006-02-03 Use of cyclolignans and new cyclolignans
US12/021,530 US7629381B2 (en) 2001-06-19 2008-01-29 Use of specific cyklolignans
US12/021,578 US7662851B2 (en) 2001-06-19 2008-01-29 Use of specific cyklolignans
AU2009201542A AU2009201542B2 (en) 2001-06-19 2009-04-20 New use of specific cyclolignans
JP2009134006A JP2009242406A (ja) 2001-06-19 2009-06-03 特定のシクロリグナン類の新しい使用
US12/508,218 US8389747B2 (en) 2001-06-19 2009-07-23 Use of specific cyklolignans
AU2010200488A AU2010200488A1 (en) 2001-06-19 2010-02-10 New use of specific cyclolignans
US12/714,107 US20100216728A1 (en) 2001-06-19 2010-02-26 New use of specific cyklolignans

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102168A SE0102168D0 (sv) 2001-06-19 2001-06-19 New use and new compounds

Publications (1)

Publication Number Publication Date
SE0102168D0 true SE0102168D0 (sv) 2001-06-19

Family

ID=20284528

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102168A SE0102168D0 (sv) 2001-06-19 2001-06-19 New use and new compounds

Country Status (15)

Country Link
US (7) US7348358B2 (sv)
EP (5) EP2186513A1 (sv)
JP (2) JP2004534078A (sv)
KR (1) KR100940055B1 (sv)
CN (3) CN1659171A (sv)
AT (1) ATE441411T1 (sv)
AU (2) AU2002311731B8 (sv)
CA (2) CA2455328C (sv)
DK (1) DK1498121T3 (sv)
ES (1) ES2333014T3 (sv)
NO (1) NO332642B1 (sv)
NZ (2) NZ530290A (sv)
PT (1) PT1498121E (sv)
SE (1) SE0102168D0 (sv)
WO (2) WO2002102805A1 (sv)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
SE0203747D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New use
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds
US7342114B2 (en) 2003-07-01 2008-03-11 California Pacific Medical Center Podophyllotoxin derivatives
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
JP4916883B2 (ja) 2003-10-15 2012-04-18 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
CN100590118C (zh) 2004-03-12 2010-02-17 阿纳里特康股份有限公司 作为类胰岛素生长因子第1类受体抑制剂的杂环化合物
WO2005097800A1 (en) * 2004-04-02 2005-10-20 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
CA2638124A1 (en) * 2006-02-24 2007-08-30 Axelar Ab Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives
CA2661024A1 (en) * 2006-08-28 2008-03-06 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
WO2009091939A1 (en) * 2008-01-18 2009-07-23 Osi Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
WO2009100349A1 (en) * 2008-02-09 2009-08-13 The Trustees Of Columbia University In The City Of New York Analogues of (-)-picropodophyllin, synthesis and uses thereof
WO2009108857A2 (en) * 2008-02-27 2009-09-03 Combithera, Inc. Combination therapy for prostate cancer
US20110191868A1 (en) * 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
WO2010054264A1 (en) 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
WO2010138686A1 (en) * 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
US7924203B2 (en) * 2009-06-12 2011-04-12 Analog Devices, Inc. Most significant bits analog to digital converter, and an analog to digital converter including a most significant bits analog to digital converter
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US20110217309A1 (en) 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2013527748A (ja) 2010-03-03 2013-07-04 オーエスアイ・ファーマシューティカルズ，エルエルシー インスリン様増殖因子１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
JP2013522215A (ja) 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー 組合わせ抗癌療法
EP2611811B1 (en) 2010-08-31 2017-01-18 Axelar AB New process for preparing cyclolignans
AU2011312905A1 (en) 2010-10-08 2013-04-11 Axelar Ab Picropodophyllin polymorphs B or C for use in cancer therapy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
JP5892508B2 (ja) * 2011-05-23 2016-03-23 国立大学法人 鹿児島大学 抗腫瘍剤及びその製造方法
WO2013124382A1 (en) * 2012-02-24 2013-08-29 Nestec S.A. Peltatin for use in the treatment of cardiovascular disorders
WO2013132262A1 (en) 2012-03-09 2013-09-12 Axelar Ab Picropodophyllin derivatives
WO2013132263A1 (en) 2012-03-09 2013-09-12 Axelar Ab Picropodophyllin derivatives for use in therapy
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP5923375B2 (ja) * 2012-04-24 2016-05-24 花王株式会社 Ｃｇｒｐ応答性促進剤
WO2014102889A1 (ja) * 2012-12-25 2014-07-03 国立大学法人鹿児島大学 抗腫瘍剤及びその製造方法
WO2014134202A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
EP2994461B1 (en) * 2013-05-10 2021-02-17 M. Alphabet 2, LLC. Methods of treating skin conditions using cyclolignan compounds
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
CN104434909A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种去氧鬼臼毒素作为胰岛素样生长因子受体拮抗剂用途
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US20190077813A1 (en) 2015-10-27 2019-03-14 California Pacific Medical Center Podophyllotoxin derivatives and their use
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
CN110669054B (zh) * 2018-07-03 2022-04-26 南京药石科技股份有限公司 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途
KR102378151B1 (ko) * 2020-05-11 2022-03-24 주식회사 제이앤씨사이언스 베타-아포피크로포도필린의 신규한 유도체

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825730A (en) * 1953-02-04 1958-03-04 Thompson Boyce Plant Res Organic compounds
US4342777A (en) * 1979-03-29 1982-08-03 The United States Of America As Represented By The Secretary Of Agriculture Polybutylbenzylphenols and benzyl-3,4-methylenedioxybenzenes in insect population control
ATE68186T1 (de) 1984-12-28 1991-10-15 Conpharm Ab Verwendung von podophyllotoxin und dessen derivaten.
NO170760C (no) * 1985-01-10 1992-12-02 Tanabe Seiyaku Co Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater
SE468213B (sv) * 1986-06-27 1992-11-23 Conpharm Ab Anvaendning av podophyllotoxin eller ett derivat daerav till framstaellning av en farmakologisk beredning foer behandling av kollagenoser, saerskilt reumatoid artrit
EP0289506A4 (en) * 1986-11-19 1990-12-12 Chemex Pharmaceuticals, Inc. Lipoxygenase inhibitors
SE464167B (sv) * 1989-07-31 1991-03-18 Analytecon Sa Topisk farmaceutisk beredning av podophyllotoxin
CN1075316A (zh) 1992-10-22 1993-08-18 布里斯托尔-米尔斯·斯奎布公司 表鬼臼毒中间体的制备方法
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
JPH09194368A (ja) * 1996-01-11 1997-07-29 Pola Chem Ind Inc ポドフィロトキシン誘導体及びそれからなる新規細胞分化誘導剤
US5726027A (en) 1996-03-08 1998-03-10 The Regents Of The University Of California Method for treatment of insulin resistance
WO1999028347A1 (en) * 1997-11-27 1999-06-10 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor
DE69900689T2 (de) 1998-06-26 2002-08-29 Quanam Medical Corp Topoisomerase inhibitoren zur restenose-prevention
DE60111352T2 (de) 2000-01-20 2006-05-04 Supratek Pharma, Inc., Montreal Podophyllotoxin-zusammensetzungen
US6894075B2 (en) * 2000-11-20 2005-05-17 Song-Bae Kim 4′-demethyl-4′-O-substituted-1-deoxypodophyllotoxin derivative and geometric isomer thereof, process for the preparation thereof and anti-cancer composition comprising the same
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
CA2520172C (en) * 2003-03-27 2012-10-02 Lankenau Institute For Medical Research Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds

Also Published As

Publication number Publication date
JP2005500300A (ja) 2005-01-06
US7348358B2 (en) 2008-03-25
JP2004534078A (ja) 2004-11-11
JP5071910B2 (ja) 2012-11-14
AU2002311731B8 (en) 2009-10-29
AU2002311731B2 (en) 2009-02-26
KR20040007743A (ko) 2004-01-24
EP1938819A3 (en) 2010-04-07
US20080119528A1 (en) 2008-05-22
CA2455328A1 (en) 2002-12-27
US20080221207A1 (en) 2008-09-11
US20060154982A1 (en) 2006-07-13
US8389747B2 (en) 2013-03-05
KR100940055B1 (ko) 2010-02-04
EP1498121B1 (en) 2009-09-02
EP1397369A1 (en) 2004-03-17
DK1498121T3 (da) 2009-12-14
ATE441411T1 (de) 2009-09-15
CA2455328C (en) 2011-09-20
NO332642B1 (no) 2012-11-26
NO20035648L (no) 2004-02-18
ES2333014T3 (es) 2010-02-16
US20090326248A1 (en) 2009-12-31
PT1498121E (pt) 2009-12-04
CN100503611C (zh) 2009-06-24
US20040167208A1 (en) 2004-08-26
CN1543466A (zh) 2004-11-03
EP1938818A3 (en) 2010-04-07
US20100216728A1 (en) 2010-08-26
US7629381B2 (en) 2009-12-08
US7709526B2 (en) 2010-05-04
CN1659171A (zh) 2005-08-24
WO2002102804A1 (en) 2002-12-27
CA2451047A1 (en) 2002-12-27
AU2002311731C1 (en) 2009-09-03
US20040186169A1 (en) 2004-09-23
EP2186513A1 (en) 2010-05-19
CA2451047C (en) 2012-10-09
CN101606929A (zh) 2009-12-23
NO20035648D0 (no) 2003-12-17
AU2002314671B2 (en) 2008-09-18
EP1938818A2 (en) 2008-07-02
WO2002102805A1 (en) 2002-12-27
EP1498121A1 (en) 2005-01-19
WO2002102804A8 (en) 2004-05-13
NZ530290A (en) 2005-05-27
EP1938819A2 (en) 2008-07-02
US7662851B2 (en) 2010-02-16
NZ530172A (en) 2004-12-24

Similar Documents

Publication Publication Date Title
SE0102168D0 (sv) New use and new compounds
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
CY1108228T1 (el) Διαρυλ-αιθερες, ως ανταγωνιστης οπιοειδους υποδοχεως
RS20060079A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
NZ514711A (en) Compounds useful as anti-inflammatory agents
EE05453B1 (et) Protsess asetidinoonvahehendite valmistamiseks
PL375409A1 (en) Method for preparing 3-halo-4,5-dihydro-1 i h /i -pyrazoles
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
IL165763A0 (en) Process for preparing 5-(1,3-oxazol-2-yl)benzoic acid derivatives
WO2004084812A3 (en) Tamandarin analogs and fragments thereof and methods of making and using
ATE380816T1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
ATE296827T1 (de) Heteropolycyclische inhibitoren
SE0301202D0 (sv) New use and new compounds
DK1562604T3 (da) Prostaglandinforbindelser til behandling af fedme
EP1253139A3 (en) Multioligoanilinated fullerenes
GB9912417D0 (en) Compounds useful in therapy
NO20033049L (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1-metylpiperidin
SE0203746D0 (sv) New compounds
CY1107515T1 (el) Συνθεση ενδιαμεσων χρησιμων στην παρασκευη τρικυκλικων ενωσεων
YU62302A (sh) Postupak za izradu jedinjenja 2-(4-alkil-1-piperazinil)- benzaldehida i benzilidenila
PE20010216A1 (es) Procedimiento para preparar derivados de 10,11-metanobenzosuberano
SE0102320D0 (sv) Novel treatment of adrenocortical hypersecretion and tumour growth
MY139960A (en) Treatment of acute myeloid leukemia with indolinone compounds
DE60214397D1 (en) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität
PE20030815A1 (es) Derivados de drechsleranol, procedimiento para su preparacion y su utilizacion